Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 270

Similar articles for PubMed (Select 22706796)

1.

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.

Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M.

Liver Transpl. 2012 Sep;18(9):1053-9. doi: 10.1002/lt.23482.

2.

Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.

Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP.

Liver Transpl. 2012 Dec;18(12):1464-70. doi: 10.1002/lt.23542.

3.

First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder.

Al Nahdi N, Ford JA, Greanya ED, Harrigan JA, Tse I, Steinbrecher UP, Erb SR, Yoshida EM.

Ann Hepatol. 2013 Jan-Feb;12(1):156-60.

4.

The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.

Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, Hohenberger W, Müller V.

Transplant Proc. 2011 Dec;43(10):3824-8. doi: 10.1016/j.transproceed.2011.08.103.

PMID:
22172854
5.

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.

Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H.

Hepatology. 2012 Mar;55(3):742-8. doi: 10.1002/hep.24724. Epub 2012 Jan 30.

PMID:
21987462
6.

Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.

Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP.

Liver Transpl. 2013 Jul;19(7):690-700. doi: 10.1002/lt.23669. Epub 2013 Jun 3.

7.

Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).

Couzigou P, Pérusat S, Bourlière M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chêne G; ANRS HC16 GAMMATRI Trial Group.

J Gastroenterol Hepatol. 2013 Feb;28(2):329-34. doi: 10.1111/jgh.12060.

PMID:
23190183
9.

Current management and perspectives for HCV recurrence after liver transplantation.

Coilly A, Roche B, Samuel D.

Liver Int. 2013 Feb;33 Suppl 1:56-62. doi: 10.1111/liv.12062. Review.

PMID:
23286847
10.

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.

Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.

Liver Transpl. 2008 Jan;14(1):53-8.

11.

Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.

Calmus Y, Duvoux C, Pageaux G, Wolf P, Rostaing L, Vanlemmens C, Botta-Fridlund D, Dharancy S, Gugenheim J, Durand F, Néau-Cransac M, Boillot O, Chazouillères O, Samelson L, Boudjema K, Samuel D.

J Hepatol. 2012 Sep;57(3):564-71. doi: 10.1016/j.jhep.2012.04.022. Epub 2012 May 18.

PMID:
22613001
12.

Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case report.

Pellicelli AM, Morrone A, Barbieri L, Andreoli A.

Ann Hepatol. 2012 Nov-Dec;11(6):951-4.

13.

Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.

Lin CC, Kabiling C, Chen CL, Lin YH, Liu YW, Wang CC, Hu TH, Chiu KW.

Transplantation. 2014 Apr 27;97 Suppl 8:S47-53. doi: 10.1097/01.tp.0000446277.36181.e7.

PMID:
24849835
14.

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR.

Hepatology. 2012 Mar;55(3):749-58. doi: 10.1002/hep.24744.

PMID:
22006408
15.

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.

Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT.

Am J Transplant. 2013 Jun;13(6):1601-5. doi: 10.1111/ajt.12209. Epub 2013 Apr 17.

16.

Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.

Gurusamy KS, Tsochatzis E, Toon CD, Xirouchakis E, Burroughs AK, Davidson BR.

Cochrane Database Syst Rev. 2013 Dec 4;12:CD006803. doi: 10.1002/14651858.CD006803.pub4. Review.

PMID:
24307460
17.

Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.

Campos-Varela I, Castells L, Esteban JI, Bes M, Rodríguez-Frías F, Sapisochin G, Allende H, Charco R, Esteban R.

Transplantation. 2012 Feb 27;93(4):450-3. doi: 10.1097/TP.0b013e318240e9dd.

PMID:
22262129
18.

Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.

Francesca Donato M, Banfi G, Cresseri D, Battista Fogazzi G, Martin P, Messa P, Fabrizi F.

Int J Artif Organs. 2013 May 17;36(5):367-72. doi: 10.5301/ijao.5000199. Epub 2013 Feb 28. Review.

PMID:
23446762
19.

Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.

Murakami E, Imamura M, Hayes CN, Abe H, Hiraga N, Honda Y, Ono A, Kosaka K, Kawaoka T, Tsuge M, Aikata H, Takahashi S, Miki D, Ochi H, Matsui H, Kanai A, Inaba T, McPhee F, Chayama K.

Antimicrob Agents Chemother. 2014;58(4):2105-12. doi: 10.1128/AAC.02068-13. Epub 2014 Jan 27.

20.

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, Van Der Werf W, Lauwers G, Liu C, Crawford JM, Davis GL, Nelson DR.

Liver Transpl. 2002 Nov;8(11):1000-6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk